SHARE
| Subject | Existing | New |
| Fund Type | Feeder Fund | Fund of Funds |
| Investment Policy | SCBGENOME (the Fund) focus on the investment in foreign mutual fund “ARK Genomic Revolution ETF (ARKG)” (Master fund), Actively Managed Exchange Traded Fund (ETF) managed by ARK Investment Management LLC., the Fund shall invest in US dollar.
The Master Fund will invest at least 80% of NAV in security of US companies and other countries having business related to Genomic Revolution theme, focusing on extending and enhancing the quality of human and other life by incorporating technological and scientific developments. The Fund will have an average net exposure in investment units of the Master Fund, in an accounting period not less than 80 % of the Fund’s NAV |
The Fund has a policy to invest in investment units of foreign funds such as CIS and/or ETF that mainly invest in securities of companies having business related Genomic Revolution theme, focusing on extending and enhancing the quality of human and other life by incorporating technological and scientific developments.
The Fund will have an average net exposure in investment units of foreign funds having characteristics as mentioned above, in an accounting period not less than 80% of the Fund’s NAV and will invest at least 2 foreign funds, with an average investment in each fund not exceeding 79% of NAV in any accounting period. Investment Proportion in investment units of foreign mutual funds depends on the discretion of the fund manager. |
| Benchmark |
The Master Fund’s performance: 100% |
Fund performance of ARK Genomic Revolution ETF : 60% and fund performance of iShares Genomics Immunology and Healthcare ETF : 40% |
| Management Style | SCBGENOME expects performance to be in accordance with the Master Fund, whereas the Master Fund aims to achieve higher performance than the Benchmark Index (Actiive Management). | SCBGENOME aims to achieve higher performance than the Benchmark Index (Active Management) |
The advantages of the change will help to streamline the portfolio management. However, this change will have no impact to SCBGENOME’s investment policy because Genomic Revolution ETF (ARKG) has been one of the existing funds.
You may contact Client Relations 0-2777-7777 ext. 0 ext. 6 during business days between 08.30 – 17.00 for any further inquiries.
Announced on 24 January 2023
SCB Asset Management Company Limited
SCB PLATINUM GLOBAL OPEN END FUND (Accumulation)
SCB LOW VOLATILITY EQUITY FUND (Dividend)
SCB LOW VOLATILITY EQUITY FUND
(Accumulation)
SCB LOW VOLATILITY EQUITY FUND (Super Savings Fund)
SCB Low Volatility Equity RMF
SCB Global Robotics Fund (Accumulation)
SCB Thai Equity CG Fund (Accumulation)
SCB DHANA ANANTA OPEN END FUND (Accumulation)
